Klaria Pharma Holding AB

Klaria Pharma is a Swedish clinical-stage biotechnology company specialized in the development of transmucosal films based on a patented alginate technology. The company's platform allows for the delivery of well-established pharmaceuticals through the oral mucosa, bypassing the gastrointestinal tract and first-pass metabolism to achieve faster onset and more reliable absorption. Klaria's lead program, a Sumatriptan Alginate Film for migraine, has successfully completed bioequivalence studies and is moving toward registration. The pipeline further includes applications for naloxone in opioid overdose and midazolam for acute epilepsy. By focusing on the reformulation of proven molecules into superior delivery formats, Klaria aims to reduce clinical risk and improve patient outcomes in neurology and emergency medicine.